Ovarian Cancer
Context Therapeutics Begins Phase I Trial of Bispecific Antibody in CLDN6-Positive Tumors
The firm will evaluate its CLDN6- and CD3 T-cell-engaging bispecific antibody in advanced or metastatic ovarian, endometrial, and testicular cancers.
Verastem Seeking FDA Approval for Avutometinib, Defactinib in KRAS-Mutant Ovarian Cancer
The FDA granted priority review to the company's avutometinib-defactinib application and expects to decide on approval in June 2025.
Accent Therapeutics Treats First Patient in Phase I DHX9 Inhibitor Trial
The study is designed to evaluate the safety, tolerability, and preliminary efficacy of ATX-559 in certain biomarker-selected cancer patients.
Epsilogen Launches Phase Ib IgE Antibody Trial in Advanced Ovarian Cancer
In the study, the firm will enroll previously treated patients whose tumors are positive for FRα based on IHC testing.
Allarity Therapeutics Providing Biomarker Analysis Services to Biotech
The firm is now inking revenue-generating contracts with other biotech companies for its drug response prediction and gene expression analysis capabilities.